Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Current Deferred Revenue (2016 - 2018)

Gsk has reported Current Deferred Revenue over the past 3 years, most recently at $277.9 million for Q4 2018.

  • Quarterly results put Current Deferred Revenue at $277.9 million for Q4 2018, down 12.77% from a year ago — trailing twelve months through Dec 2018 was $277.9 million (down 12.77% YoY), and the annual figure for FY2018 was $288.5 million, down 6.69%.
  • Current Deferred Revenue for Q4 2018 was $277.9 million at Gsk, down from $318.6 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for GLAXF hit a ceiling of $318.6 million in Q4 2017 and a floor of $196.4 million in Q4 2016.
  • Median Current Deferred Revenue over the past 3 years was $277.9 million (2018), compared with a mean of $264.3 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 62.22% in 2017 and later dropped 12.77% in 2018.
  • Gsk's Current Deferred Revenue stood at $196.4 million in 2016, then skyrocketed by 62.22% to $318.6 million in 2017, then dropped by 12.77% to $277.9 million in 2018.
  • The last three reported values for Current Deferred Revenue were $277.9 million (Q4 2018), $318.6 million (Q4 2017), and $196.4 million (Q4 2016) per Business Quant data.